Bristol Myers Squibb (CELG-RI) Other Working Capital Changes (2009 - 2026)

Bristol Myers Squibb (CELG-RI) reported Other Working Capital Changes of $1.6 billion for Q1 2026, up 54.49% year-over-year from $1.1 billion in Q1 2025, and up 253.18% quarter-over-quarter from -$1.1 billion in Q4 2025.

Bristol Myers Squibb (CELG-RI) Other Working Capital Changes (2009 - 2026) Analysis & Trends

Bristol Myers Squibb (CELG-RI) has 18 years of Other Working Capital Changes data on file, last reported at $1.6 billion in Q1 2026.

  • Other Working Capital Changes for Q1 2026 came in at $1.6 billion, up 54.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $106.0 million (up 161.27% YoY), and the FY2025 annual result was -$471.0 million, up 24.52% from the prior year.
  • Other Working Capital Changes advanced to $1.6 billion in Q1 2026 per CELG-RI's latest filing, from -$1.1 billion in the prior quarter.
  • Over five years, Other Working Capital Changes peaked at $1.6 billion in Q1 2026 and troughed at -$1.1 billion in Q4 2025.
  • A 5-year average of $106.9 million and a median of -$167.0 million in 2024 frame the typical range for Other Working Capital Changes.
  • The sharpest annual moves came in 2022 and 2024: Other Working Capital Changes jumped 185.27% in 2022, then tumbled 383.05% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at -$700.0 million in 2022, then jumped by 59.57% to -$283.0 million in 2023, then tumbled by 156.18% to -$725.0 million in 2024, then sank by 47.31% to -$1.1 billion in 2025, then jumped by 253.18% to $1.6 billion in 2026.
  • Business Quant data shows CELG-RI's Other Working Capital Changes at $1.6 billion in Q1 2026, -$1.1 billion in Q4 2025, and -$240.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Bristol Myers Squibb - - 8.07 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.64 Bn
Mar 31, 2026 1.64 Bn
Dec 31, 2025 -1.07 Bn
Dec 31, 2025 -1.07 Bn
Sep 30, 2025 -240.00 Mn
Sep 30, 2025 -240.00 Mn
Jun 30, 2025 -222.00 Mn
Jun 30, 2025 -222.00 Mn
Mar 31, 2025 1.06 Bn
Mar 31, 2025 1.06 Bn
Dec 31, 2024 -725.00 Mn
Dec 31, 2024 -725.00 Mn
Sep 30, 2024 -167.00 Mn
Sep 30, 2024 -167.00 Mn
Jun 30, 2024 -340.00 Mn
Jun 30, 2024 -340.00 Mn
Mar 31, 2024 608.00 Mn
Mar 31, 2024 608.00 Mn
Dec 31, 2023 -283.00 Mn
Dec 31, 2023 -283.00 Mn